MarketPeel
Insider Trading Intelligence
Pricing
…
AM

Andrew Paul Mazar

ACTU
CHIEF OPERATING OFFICER · ACTUATE THERAPEUTICS, INC. · CIK 0001727393
FILING MIX · LIFETIME44%/56%
BUYS
15
SELLS
19
TOTAL VALUE
$38.01M
COMPANIES
2
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
377,026
AVG SELL PX
$53.37
TRADE KIND
SHOWING 34 / 34
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 3 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Andrew Paul Mazar, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+85.71%-14.73%-0.24%-14.49%-20.76%—
14d7+85.71%-16.83%-2.25%-14.57%-28.14%—
30d7+71.43%-16.16%+1.02%-17.18%-29.16%—
60d7+85.71%-36.03%+4.95%-40.98%-57.12%—
90d7+100.00%-39.00%+4.85%-43.85%-55.42%—
180d7+85.71%-27.23%+12.42%-39.65%-66.97%—
1y7(1 pending)+83.33%-52.96%+14.56%-67.52%-86.41%—
2y7(2 pending)+100.00%-65.19%+7.55%-72.74%-72.74%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ACTU · 105,000 shares · as of Apr 1, 2026
027,58755,17382,760110,3462026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 15 buys / 19 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ACTU
ACTUATE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
105,000——105,000Apr 1, 2026Apr 1, 2026 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
550,229$63.61$35.00M272,026Sep 24, 2025Sep 26, 2025 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
33,334$35.00$1.17M822,255Apr 2, 2025Apr 4, 2025 ↗View →
ACTU
ACTUATE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
51,046——51,046Apr 1, 2025Apr 2, 2025 ↗View →
ACTU
ACTUATE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
110,346——110,346Apr 1, 2025Apr 2, 2025 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Scientific Officer
1,606——22,595.8Mar 31, 2022Apr 1, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
1,606——88,792Mar 31, 2022Apr 1, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
471$2.55$1.2K22,124.8Mar 31, 2022Apr 1, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
67,251——90,398Feb 2, 2022Feb 4, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
88,874——88,874Feb 2, 2022Feb 4, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Scientific Officer
1,937——21,660.8Jan 1, 2022Jan 4, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
671$3.21$2.2K20,989.8Jan 1, 2022Jan 4, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
1,937——3,874Jan 1, 2022Jan 4, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
1,606——19,273Dec 31, 2021Jan 4, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
556$3.21$1.8K19,723.8Dec 31, 2021Jan 4, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Scientific Officer
1,606——20,279.8Dec 31, 2021Jan 4, 2022 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Scientific Officer
1,606——19,144.8Sep 30, 2021Oct 1, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
1,606——20,879Sep 30, 2021Oct 1, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
471$4.87$2.3K18,673.8Sep 30, 2021Oct 1, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
942$5.89$5.5K17,538.8Jun 30, 2021Jul 2, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Scientific Officer
3,212——18,480.8Jun 30, 2021Jul 2, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
3,212——22,485Jun 30, 2021Jul 2, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
42,467$13.30$564.8K249,200Feb 11, 2021Feb 16, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
24,224$14.09$341.3K224,976Feb 11, 2021Feb 16, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
29,996$15.12$453.5K194,980Feb 11, 2021Feb 16, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
11,929$16.90$201.6K166,667Feb 11, 2021Feb 16, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
16,384$16.44$269.4K178,596Feb 11, 2021Feb 16, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
36,077——36,077Jan 26, 2021Jan 28, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
25,697——31,508Jan 26, 2021Jan 28, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
1,937——5,811Jan 1, 2021Jan 5, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Scientific Officer
1,937——15,939.8Jan 1, 2021Jan 5, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Scientific Officer
671$6.12$4.1K15,268.8Jan 1, 2021Jan 5, 2021 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
7,748——7,748Jan 31, 2020Feb 20, 2020 ↗View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
32,193——32,193Jan 31, 2020Feb 20, 2020 ↗View →
Other insiders · ACTU
Loading peer insiders…
About this filer
CIK 0001727393
ROLE
Chief Operating Officer
PRIMARY
ACTU
COMPANIES
2
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001727393DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback